EU backs AstraZeneca, Daiichi's ENHERTU

EU backs AstraZeneca, Daiichi's Enhertu for breast cancer treatment post endocrine therapy
The European Union's health regulator on Friday backed AstraZeneca and Daiichi Sankyo's drug Enhertu as a breast cancer treatment for patients who received endocrine therapy but are not suitable for additional hormone treatments.
AstraZeneca, Daiichi Sankyo’s Enhertu recommended for approval in EU
AstraZeneca (AZN) and Daiichi Sankyo’s (DSNKY) trastuzumab deruxtecan has been recommended for approval in the European Union as a monotherapy
CHMP Recommends Approval of AstraZeneca, Daiichi Sankyo's Enhertu in HER2-Ultralow Breast Cancer
Approval would expand the use of Enhertu to breast cancer patients with nearly undetectable HER2 levels in their tumors.
AstraZeneca breast cancer therapy wins recommendation for EU approval
(Alliance News) - AstraZeneca PLC on Friday said its breast cancer therapy, Enhertu, which is being developed jointly with Tokyo-based pharmaceutical company Daiichi Sankyo Co Ltd, has been recommended for approval in the EU.
AstraZeneca Enhertu recommended for approval in EU by CHMP
Daiichi Sankyo and AstraZeneca’s Enhertu has been recommended for approval in the European Union as a monotherapy for the treatment of adult patients with unresectable or metast
AstraZeneca's metastatic breast cancer treatment gets EU recommendation
AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo said on Friday that the European Medicines Agency (EMA) endorsed ENHERTU for the treatment of metastatic breast cancer. Issuing a positive recommendation, EMA’s Committee for Medicinal Products for Human Use (CHMP)  recommended the marketing authorization for ENHERTUas a monotherapy for the treatment of
Investing2d
AstraZeneca’s Enhertu gains CHMP nod for breast cancer
Susan Galbraith, Executive Vice President of Oncology Haematology R&D at AstraZeneca (NASDAQ:AZN), highlighted the potential for Enhertu to become the first HER2-directed treatment for this ...
Q3 EPS Estimates for AstraZeneca Reduced by Zacks Research
Investment analysts at Zacks Research dropped their Q3 2025 earnings per share (EPS) estimates for shares of AstraZeneca in a report issued on Thursday, February 27th. Zacks Research analyst R.
AstraZeneca Post 2024 Earnings: Unwanted Headwinds Warrant Downgrade To Hold
AstraZeneca PLC outperforms 2024 earnings estimates but faces challenges in 2025. Read why AZN patent expiries and mixed ...
Reuters3d
AstraZeneca PLC
UK stocks down for third day as mixed earnings weigh February 20, 2025 AstraZeneca will buy longtime partner FibroGen's China unit for about $160 million to gain rights to its anemia drug in the ...